X-154411870-C-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM1BS2
The NM_000116.5(TAFAZZIN):āc.27C>Gā(p.Phe9Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000499 in 1,201,304 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 5 hemizygotes in GnomAD. Variant has been reported in ClinVar as Uncertain significance (ā ā ).
Frequency
Genomes: š 0.000027 ( 0 hom., 3 hem., cov: 24)
Exomes š: 0.0000028 ( 0 hom. 2 hem. )
Consequence
TAFAZZIN
NM_000116.5 missense
NM_000116.5 missense
Scores
7
4
6
Clinical Significance
Conservation
PhyloP100: 2.50
Genes affected
TAFAZZIN (HGNC:11577): (tafazzin, phospholipid-lysophospholipid transacylase) This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
DNASE1L1 (HGNC:2957): (deoxyribonuclease 1 like 1) This gene encodes a deoxyribonuclease protein that shows high sequence similarity to DNase I. The encoded protein is localized to the endoplasmic reticulum and modified by N-linked glycosylation. Alternate transcriptional splice variants encoding the same protein have been observed. [provided by RefSeq, Jan 2015]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM1
In a chain Tafazzin (size 261) in uniprot entity TAZ_HUMAN there are 37 pathogenic changes around while only 4 benign (90%) in NM_000116.5
BS2
High Hemizygotes in GnomAd4 at 3 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
TAFAZZIN | NM_000116.5 | c.27C>G | p.Phe9Leu | missense_variant | 1/11 | ENST00000601016.6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
TAFAZZIN | ENST00000601016.6 | c.27C>G | p.Phe9Leu | missense_variant | 1/11 | 1 | NM_000116.5 |
Frequencies
GnomAD3 genomes AF: 0.0000267 AC: 3AN: 112266Hom.: 0 Cov.: 24 AF XY: 0.0000871 AC XY: 3AN XY: 34436
GnomAD3 genomes
AF:
AC:
3
AN:
112266
Hom.:
Cov.:
24
AF XY:
AC XY:
3
AN XY:
34436
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD4 exome AF: 0.00000275 AC: 3AN: 1089038Hom.: 0 Cov.: 31 AF XY: 0.00000559 AC XY: 2AN XY: 358046
GnomAD4 exome
AF:
AC:
3
AN:
1089038
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
358046
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000267 AC: 3AN: 112266Hom.: 0 Cov.: 24 AF XY: 0.0000871 AC XY: 3AN XY: 34436
GnomAD4 genome
AF:
AC:
3
AN:
112266
Hom.:
Cov.:
24
AF XY:
AC XY:
3
AN XY:
34436
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
3-Methylglutaconic aciduria type 2 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 06, 2022 | This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 9 of the TAZ protein (p.Phe9Leu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with TAZ-related conditions. ClinVar contains an entry for this variant (Variation ID: 840746). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Cardiovascular phenotype Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Dec 01, 2020 | The p.F9L variant (also known as c.27C>G), located in coding exon 1 of the TAZ gene, results from a C to G substitution at nucleotide position 27. The phenylalanine at codon 9 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
.;.;.;.;.;T;.;T
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
.;T;T;.;T;T;T;T
M_CAP
Pathogenic
D
MetaRNN
Uncertain
D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
.;L;L;.;L;L;.;.
MutationTaster
Benign
D;D;D;D;D;D;D;D;D
PrimateAI
Uncertain
T
PROVEAN
Uncertain
.;.;D;.;.;.;D;D
REVEL
Pathogenic
Sift
Benign
.;.;T;.;.;.;T;T
Sift4G
Benign
T;T;T;T;T;T;T;T
Polyphen
0.12, 0.17, 0.23, 0.98
.;B;B;.;B;D;.;.
Vest4
0.44, 0.42, 0.58, 0.47, 0.50
MutPred
Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);Gain of glycosylation at P14 (P = 0.0722);
MVP
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at